梯瓦制药

最新新闻

• 公司公告
  TEVA PHARMACEUTICAL INDUSTRIES | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-The Phoenix Holdings Ltd.(4.83%)
  SEC · 2024/4/9
• Scotiabank Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Raises Target Price to $47
  \u5e02\u573a\u8d44\u8baf · 2026/10/2
• 公司公告
  Teva Pharmaceutical Industries | 3: Initial statement of beneficial ownership of securities-Officer McAvoy David R.
  SEC · 2024/3/6
• 公司公告
  Teva Pharmaceutical Industries | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-The Phoenix Holdings Ltd.(4.83%)
  SEC · 2024/4/9
• 评级变动
  Goldman Sachs Initiates Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Announces Target Price $50
  \u5e02\u573a\u8d44\u8baf · 2026/9/3
• TD Cowen Initiates Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Announces Target Price $55
  \u5e02\u573a\u8d44\u8baf · 2026/10/2
• 评级变动
  Jefferies Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Maintains Target Price $40
  \u5e02\u573a\u8d44\u8baf · 2026/9/3
• 评级变动
  Piper Sandler Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Maintains Target Price $44
  \u5e02\u573a\u8d44\u8baf · 2026/8/27
• 评级变动
  J.P. Morgan Sticks to Their Buy Rating for Teva (TEVA)
  TipRanks · 2026/9/25
• 公司公告
  Teva Pharmaceutical Industries | SC 13G: Statement of acquisition of beneficial ownership by individuals-The Phoenix Holdings Ltd.(5.40%)
  SEC · 2024/2/1
• BofA Securities Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Maintains Target Price $43
  \u5e02\u573a\u8d44\u8baf · 2026/10/9
• 评级变动
  UBS Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Raises Target Price to $48
  \u5e02\u573a\u8d44\u8baf · 2026/9/4
• 评级变动
  Barclays Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Raises Target Price to $42
  \u5e02\u573a\u8d44\u8baf · 2026/8/12
• 评级变动
  Evercore Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/9/3
• 公司公告
  Teva Pharmaceutical Industries | 4: Statement of changes in beneficial ownership of securities-Officer McAvoy David R.
  SEC · 2024/3/6
• 评级变动
  Scotiabank Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Maintains Target Price $40
  \u5e02\u573a\u8d44\u8baf · 2026/9/3
• 评级变动
  BofA Securities Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Raises Target Price to $43
  \u5e02\u573a\u8d44\u8baf · 2026/9/24
• 评级变动
  Leerink Partners Initiates Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Announces Target Price $45
  \u5e02\u573a\u8d44\u8baf · 2026/9/9
• J.P. Morgan Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/9/25
• Piper Sandler Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Raises Target Price to $44
  \u5e02\u573a\u8d44\u8baf · 2026/10/1
• Teva Launches LongActingImpact.com to Advance Understanding of Earlier, Effective and Uninterrupted Schizophrenia Care
  GlobeNewswire · 2026/9/16
• Teva Pharmaceutical Industries(TEVA.US) Director Sells US$14.36 Million in Common Stock
  \u5e02\u573a\u8d44\u8baf · 2026/9/23
• 评级变动
  UBS Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Maintains Target Price $42
  \u5e02\u573a\u8d44\u8baf · 2026/8/7
• Teva to Host Conference Call to Discuss Third Quarter 2026 Financial Results on November 3, 2026 at 8 A.m. ET
  GlobeNewswire · 2026/9/24

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。